

WO 2005/058244 A2

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number  
WO 2005/058244 A2

(51) International Patent Classification<sup>7</sup>:

A61K

(21) International Application Number:

PCT/US2004/041788

(22) International Filing Date:

15 December 2004 (15.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/529,517 15 December 2003 (15.12.2003) US

(71) Applicant (for all designated States except US): ALEXION PHARMACEUTICALS, INC. [US/US]; 352 Knotter Drive, Cheshire, CT 06410 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BOWDISH, Katherine, S. [US/US]; 13754 Boquita Drive, Del Mar, CA 92014 (US). KRETZ-ROMMEL, Anke [US/US]; 4535 Kensington Drive, San Diego, CA 92116 (US).

(74) Agent: FARBER, Mark; Alexion Pharmaceuticals, Inc., 352 Knotter Drive, Cheshire, CT 06410 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


**Published:**

— without international search report and to be republished upon receipt of that report


[Continued on next page]

(54) Title: NOVEL ANTI-DC-SIGN ANTIBODIES

A  
IgG1 library



B  
IgG2a library



(57) Abstract: Antibodies to DC-SIGN are disclosed which are capable of modulating the interaction of dendritic cells and T cells. In some embodiments, the antibodies inhibit the interaction of dendritic cells and T cells. In other embodiments, the antibodies are combined with peptides which are internalized in dendritic cells and presented to T cells, thereby generating an immune response to the peptide. The antibodies of the present disclosure may, in some embodiments, be useful in blocking viral binding, infection, and transmission.



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*